Taro Penalties Exceed $400m As It Admits Fixing Prices With Sandoz

Criminal Penalty And Civil Damages Announced

In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Department of Justice
Taro has agreed to cooperate fully with the DoJ Antitrust Division’s ongoing criminal investigation • Source: Shutterstock

Taro Pharmaceutical Industries’ US subsidiary has become the fifth pharmaceutical company to admit that it conspired to fix the prices of generic medicines, agreeing to pay a $205.7m criminal penalty as part of a three-year deferred prosecution agreement with the US Department of Justice.

The Sun Pharma affiliate – which admitted that its sales affected by the charged conspiracies “exceeded $500m” – is also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By 

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

US Tariff Overhang Weighs on Chinese API Exports

 

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By 

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.